ACTIVE HALF-LIFE
2 days
CLASSIFICATION
Non-steroidal aromatase inhibitor
DOSAGE
0.5 - 2.5 mg/day
ACNE
No
WATER RETENTION
No
HBR
No
HEPATOTOXICITY
No
AROMATIZATION
No
MANUFACTURER
Euro-Pharmacies - US
LAB TEST
See Document
WAREHOUSE
USA Warehouse 3
SUBSTANCE
Letrozole
Introducing Letrozolexin, a powerful non-steroidal aromatase inhibitor designed to target and suppress estrogen synthesis. As a leading third-generation aromatase inhibitor, Letrozolexin effectively and reversibly blocks the aromatase enzyme, making it a crucial ally in the fight against estrogen-dependent breast cancer cells.
Aromatase, a cytochrome P-450 enzyme present in numerous tissues such as the liver, breast, and premenopausal ovaries, plays a pivotal role in converting androgens like testosterone and androstenedione into estrogens, the final step in estrogen production. Letrozolexin steps in to disrupt this process by competitively binding to the enzyme's heme group, successfully halting estrogen production without affecting the synthesis of essential mineralocorticoids and corticosteroids. Unlike tamoxifen, which binds to estrogen receptors to exert its anti-estrogenic effects, Letrozolexin tackles the source directly.
Approved by the United States Food and Drug Administration (FDA), Letrozolexin is a trusted treatment for local or metastatic hormone receptor-positive breast cancer, even in cases with indeterminate receptor status in postmenopausal women. While it can lead to side effects associated with reduced estrogen levels, such as potential osteoporosis, it is often prescribed alongside supportive medications like Fosamax to minimize these risks.
Research highlights that Letrozolexin can significantly lower estrogen levels by up to 98%, all while boosting testosterone. This anti-estrogen effect is particularly cherished by athletes and bodybuilders during steroid cycles, as it helps combat bloating and prevents gynecomastia, a common side effect of certain anabolic steroids. However, caution is advised, as doses over 2.5 mg per day may temporarily impact libido, and daily use exceeding 5 mg could pose kidney risks.
Moreover, Letrozolexin has been noted for its potential to delay the fusion of growth plates in adolescents, potentially enhancing growth hormone efficacy, making it a valuable treatment option for children and teens experiencing short stature.